The Scleroderma Research Foundation announced that it has launched a new platform clinical trial to advance potential treatment options for patients with scleroderma. The new international, multicenter, randomized, double-blind, placebo-controlled, phase II CONQUEST trial will initially focus on interstitial lung disease secondary to scleroderma and will address other scleroderma manifestations in later iterations. “I have been involved in numerous recent clinical trials for our [patients with] scleroderma. It was clear … that a radical reworking of how we approach clinical trials in [scleroderma] was required,” concluded principal investigator Dinesh Khanna, MD, Professor of Medicine at the University of Michigan. The CONQUEST trial will seek to enroll patients across 130 health-care centers in 22 countries.
October 05, 2023